Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
November 24 2020 - 07:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to
Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of November 2020
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in its
charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On November 24, 2020, Can-Fite BioPharma Ltd.
issued a press release entitled “Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’
in the NASH Category of the American Association of Liver Diseases (AASLD)”. A copy of this press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: November 24, 2020
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2023 to Mar 2024